Silvercrest Asset Management Group Reduces $8M in ICU Medical, Inc. ($ICUI)
Silvercrest cut its ICU Medical shares by 14.9%, now holding 323,676 shares worth $47.88 million.
Key Points
- Silvercrest Asset Management reduced its stake in ICU Medical by 14.9%, selling 56,787 shares to hold 323,676 shares valued at $47.88 million as of the latest 13F filing.
- ICU Medical, with a market cap of about $3.71 billion, trades on the NasdaqGS under the ticker ICUI and has a P/E ratio of 80.15.
- Analyst firms including BTIG and Needham have recently rated ICU Medical as a 'buy', with price targets ranging from $163 to $180.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Silvercrest Asset Management Group has reduced its position in ICU Medical, Inc. (NASDAQ: ICUI) by 14.9%, according to its latest 13F filing with the SEC. The firm sold 56,787 shares, bringing its total holdings to 323,676 shares, valued at approximately $47.88 million.
Silvercrest Asset Management Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Silvercrest's ICU Medical Position
Silvercrest Asset Management trimmed its stake in ICU Medical by selling 56,787 shares, reducing its holdings by 14.9% to 323,676 shares. The value of its position now stands at about $47.88 million. This adjustment was reported in the firm's latest quarterly filing.
Other Institutional Activity in ICU Medical
Among other institutional investors, BlackRock, Inc. increased its holdings by 20,167 shares, ending with 3,608,322 shares valued at roughly $466.01 million. Janus Henderson Group PLC added 99,256 shares, now holding 2,676,012 shares worth about $345.61 million, marking a 3.9% increase. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, each holding 1,437,676 and 1,111,875 shares valued at $185.68 million and $143.60 million, respectively. Conversely, Fuller & Thaler Asset Management, Inc. reduced its stake by 45,260 shares, now holding 1,220,539 shares valued at approximately $157.63 million.
ICU Medical, Inc. Stock Down 15.5%
On Tuesday, shares of ICU Medical traded near $147.93. The company, with a market cap of about $3.71 billion, has a P/E ratio of 80.15 and a forward P/E of 15.94. Its beta is 0.778, indicating lower volatility than the market. The stock's 52-week range is between $107.00 and $160.29, with a 50-day moving average of $130.76 and a 200-day moving average of $135.24. ICU Medical's current ratio is 2.34, and its quick ratio is 0.95, with a debt-to-equity ratio of 63.62.
$ICUI stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
ICU Medical reported revenues of approximately $2.16 billion with a slight decline of 12.3% in revenue growth. The company's earnings per share (EPS) is $1.85, with a net margin of 2.15% and a return on equity (ROE) of 2.26%. The next earnings release is scheduled for August 6, 2026.
Insider Buying and Selling at ICU Medical, Inc.
Recent insider activity at ICU Medical includes sales by President Daniel Woolson, who sold 2,123 shares on May 22, 2026, at an average price of $132.21. Virginia Ruth Sanzone, VP and General Counsel, sold 2,447 shares on May 14, 2026, at $124.08. On May 13, 2026, insiders David Greenberg, David Hoffmeister, and Elisha Finney each bought 1,254 shares, though the transaction price was not disclosed.
Analysts Set New Price Targets
On June 15, 2026, BTIG initiated coverage on ICU Medical with a "buy" rating and a $170 price target. Needham upgraded the stock to "buy" with a $165 target on May 27, 2026. Other firms like Keybanc and Piper Sandler maintained their "buy" ratings, setting targets between $163 and $180. The consensus among analysts is a strong buy, with a mean target price of $172.50 based on eight opinions.
About ICU Medical
ICU Medical, Inc., headquartered in San Clemente, California, specializes in developing and selling medical products for infusion therapy, vascular access, and vital care. The company offers a range of products, including infusion pumps, catheter devices, and IV therapy solutions, serving customers like hospitals and home health care providers worldwide. It was founded in 1984 and is led by CEO Mr. Vivek Jain, employing around 13,000 people.
Bottom Line
Silvercrest Asset Management's reduction in ICU Medical holdings reflects a notable shift in its investment strategy. Investors keep a close eye on these filings for insights into institutional sentiment. While 13F filings are backward-looking, they offer a snapshot of fund activity and potential trends in the stock market.
Get ICU Medical, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ICUI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.